Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.17K$15.17Kderived+39.2% vs Q4 2019 Net Income-$2.03M-$2.03MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$9,742N/M Operating Incomederived-$346,218N/M Operating Cash Flowderived-$352,823N/M Margins · derivedGross margin-64.2%+237.7 pt vs Q4 2019
Operating margin-2282.4%+1553.9 pt vs Q4 2019
Net margin-13405.7%+23639.7 pt vs Q4 2019
ended Dec 31, 2020 · filed Sep 8, 2021 · 251 d after period end